engleski

Direct-acting antiviral agents in the treatment of chronic hepatitis C infection in southern Croatia

Background and Aims Croatia is one of the 28 European Union member states with the population of 4, 171, 000 inhabitants. In southern part of Croatia, in which this research was carried out, there are 860, 000 inhabitants. Treatment of HCV with direct-acting antiviral agents (DAA) began in 2014. Methods In the period between August 2015 and October 2018, 230 HCV infected patients in three hospitals in southern Croatia completed therapy with DAA. Majority of patients, 125/230 (55%) were treatment-experienced (TE). Among them, 72% were relapsers, 23% non-responders, and 2.5% partial responders. Considering genotype distribution, most of the patients were genotype 1 (62%), followed by G3 (33%), G4 (4%) and G2 (1%). In all patients fibrosis was determinated by FibroScan® (range 7.1-70.6 kPa). Majority of patients (80%) had cirrhosis (F4), 8% had fibrosis 3 i 12% had fibrosis 2. Results Among 230 patients with chronic HCV infection, 82 (35.65%) were treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin (RBV) ; 41 (17.82%) with ledipasvir/sofosbuvir +/- RBV ; 37 (16%) with sofosbuvir/velpatasvir +/- RBV and 37 (16%) with glecaprevir/pibrentasvir ; 15 (6.52%) with sofosbuvir + RBV and finally, 18 (7.82%) with elbasvir/grazoprevir +/- RBV. SVR 12 weeks after completion of therapy was available for all patients. Only 3 patients did not achieve SVR which gives the SVR rate of 98.69%. Conclusions Treatment of chronic HCV with DAAs in southern Croatia is in accordance with other real-life studies. Most patients (88%) had significantly impaired liver function – fibrosis 3 and 4 (F3/F4) and only 12% had fibrosis 2 (F2).

Direct-acting antiviral agents ; chronic hepatitis C ; southern Croatia

nije evidentirano